In 74 adults with recurrent acute pancreatitis, naldemedine vs placebo for up to 12 months gave a numerically lower, borderline non-significant risk of recurrence (HR 0.54; 95% CI 0.29-1.01; p=0.05). No differences in secondary outcomes or safety.
RCTn = 74
Cook et al. Naldemedine for the Prevention of Recurrent Acute Pancreatitis: A Randomised, Double-Blind, Placebo-Controlled Trial